  To study the curative effect and safety of menchymal stem cell infusion in treatment of children with refractory late-onset hemorrhagic cystitis<disease> ( LOHC) after allogeneic HSCT. Thirty cases of children with refractory LOHC after allo-HSCT in our department between December 2010 and July 2016 were analyzed retrospectively , out of 30 cases 7 received MSC treatment. The used MSC of all were four-to-five generation MSC from bone<disease> marrows<disease> of third party donors , and were infused into patients with ( 1.87 ± 0.456) × 10 In 30 children with refractory LOHC , the hematuria<symptom> difficultly reached the remission after routine hydration , alkalizing and antiviral therapy , Among 25 cases who were received methylprednisolone , MTX and CTX therapy , 7 cases received MSC infusion for 1-4 times with dose of ( 1.87 ± 0.456) × 10 The MSC treatment is safe and effective for refractory LOHC after allo-HSCT.